* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Antipsychotics
Pharmaceutical industry wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Nicotinic agonist wikipedia , lookup
Serotonin syndrome wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
5-HT3 antagonist wikipedia , lookup
5-HT2C receptor agonist wikipedia , lookup
Drug interaction wikipedia , lookup
Prescription costs wikipedia , lookup
Toxicodynamics wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Neuropharmacology wikipedia , lookup
Atypical antipsychotic wikipedia , lookup
ANTIPSYCHOTICS Sharini Chandra s140044 Able to reduce psychotic symptoms in a wide variety of conditions, including schizophrenia, bipolar disorder, psychotic depression and drug induced psychoses Also known as neuroleptics Two major classes: Dopamine receptor antagonist (Typical antipsychotics or first generation) chlorpromazine, haloperidol Serotonin-dopamine antagonist (Atypical antipsychotics or second generation) - risperidone, clozapine, olanzapine The atypical antipsychotic drug is now the most widely used type of antipsychotic drug. PRINCIPLES OF ANTIPSYCHOTICS • Five major principles: 1) Clinicians should define the target symptoms to be treated 2) An antipsychotic that has worked well in the past should be used again. In absence of such information, the choice of an antipsychotic is usually based on the side effect profile. 3) The minimum length of an antipsychotic trial is 4-6 weeks of adequate dosages. If the trial is unsuccessful, a different antipsychotic drug, from a different class can be tried 4) In general, the use of more than one antipsychotic drug at any one time is rarely indicated. 5) Patients should be maintained on the lowest possible effective dosage of medication. DOPAMINE RECEPTOR ANTAGONIST (TYPICAL ANTIPSYCHOTICS) • Post-synaptic blockade of dopamine D2 receptors • High potency- haloperidol, low potency - chlorpromazine • Effective in the treatment of schizophrenia particularly of the positive symptoms (eg. Delusions and hallucinations) • Two major shortcomings: • Only a small percentage(25%) are helped enough to recover a reasonable amount of normal mental functioning. • Dopamine receptor antagonists are associated with adverse effects like akathisia, parkinsonian-like symptoms of rigidity and tremor, tardive dyskinesia and neuroleptic malignant syndrome. SEROTONIN- DOPAMINE ANTAGONIST (ATYPICAL ANTIPSYCHOTICS) • First line of antipsychotics • Block dopamine receptors but with less affinity • Since it blocks nigrostriatal D2 receptors less- extrapyramidal side effects occur less frequently • Effective for a broader range of patients with schizophrenia than dopamine receptor antagonist. • Effective as haloperidol for positive symptoms for schizophrenia, also is effective for negative symptoms since it blocks serotonin receptors and cause few extrapyramidal symptoms. DOPAMINE RECEPTOR ANTAGONIST (TYPICAL ANTIPSYCHOTICS) • Chlorpromazine • used in the treatment: schizophrenia, nausea and vomiting and severe behavioural disorders in children • Lipid soluble so are well absorbed orally and concentrate in CNS • Subject to first pass metabolism and bioavailability ranges from 10%-80% • Peak plasma level: 1-4 hrs after oral administration and 15-30 minutes after IM injection • Therapeutic effect: 6 weeks- 6 months • Metabolised in the liver and excreted by kidneys • Adverse effects: orthostatic hypotension, anticholinergic and extrapyramidal side effects ( akathisia, dystonia, drug induced parkinsonism and tardive dyskinesia) • Dosage: 50 – 600mg CONTRAINDICATIONS • Use with caution in patients with breast cancer, cardiovascular disease, severe liver impairment, hyperthyroidism, Parkinson’s disease and epilepsy • Avoid use in alcohol abusers, in pregnant women, during lactation and in people frequently exposed to sunlight. • Haloperidol • Competitively blocks D2 receptors in the mesolimbic system and causes an increased turnover of brain dopamine to produce its antipsychotic effect • Associated with significant degree of extrapyramidal effects but has less effect on noradrenergic receptors • Useful antipsychotic and antiemetic and is used to treat severe behavioural problems in children and in acute mania • Rapidly absorbed from the GI • Peak plasma level: 2-6 hrs of oral intake, 20 mins if given IM • Metabolised in the liver and excreted by kidneys • Dosage: 0.5 – 12mg SIDE EFFECTS OF TYPICAL ANTIPSYCHOTICS • Movement disorders: Dystonia (muscle spasm) Parkinsonism (tremor, slow movements) Akathisia (restlessness) • Tardive Dyskinesia: Uncontrollable muscle spasms resulting in twisting of body or neck. Occurs in 5% of people taking medication. • Sedation • Galactorrhea (stimulation of milk secretions) • Sexual dysfunction in males • Liver disorder (rare) SEROTONIN- DOPAMINE ANTAGONIST (ATYPICAL ANTIPSYCHOTICS) • Risperidone And Olanzapine • Block both 5-HT2 and dopamine D2 receptors • Less sedating, cause fewer anticholinergic effects and do not have the same potential to cause serious agranulocytosis Risperidone • Risperidone is widely used atypical drug • A growing body of evidence supports its role as a first- line agent for first break, mildly to moderately ill patients and for severely ill, treatment refractory patients • dosage: 0.5- 6.0mg • Adverse effects: Movement disorder, gastric distress, mild sedation • Olanzapine • Olanzapine has been approved recently for use in treatment of acute manic episodes associated with bipolar disorder • Less likely to produce extrapyramidal symptoms • It is useful first line agent, in that patients who do not respond to one serotonin – dopamine antagonist may respond to another • 85% is adsorbed from GIT • Peak conc. : 5 hrs • Half life : 31 hrs • Adverse effect of olanzapine : sexual dysfunction, weight gain, mild liver dysfunction, constipation • Olanzapine ( oral dosage ) : 5 -20 mg • Clozapine • Second line drug • Antagonises D1,D2 and D4 dopamine receptors, with less affinity for D2 receptors, so it is less likely to induce extrapyramidal effects. • Also antagonises 5-HT2, a1 adrenoceptors and histamine H1 receptors • Useful for patients with tardive dyskinesia • Clozapine requires strict monitoring in light of its potential to cause neutropenia, agranulocytosis, myocarditis, toxic megacolon and cardiomyopathy • Peak plasma conc. Reached in 2 hrs • Half life: 12 hrs • Adverse effects: drowsiness, seizure, severe constipation and orthostatic hypotension • Recommended use: Clozapine 12.5 mg orally, twice daily initially, increasing as tolerated and according to patient response. Usual effective daily dose is 200 to 600 mg. The maximum dose is 900 mg daily, but this is not usually required METABOLIC SYNDROME • Weight gain, diabetes, and dyslipidemia are the components of metabolic syndrome usually associated with second generation antipsychotics, along with the consequent risks of diabetic ketoacidosis and cardiovascular disease • The mechanism is not entirely clear, but there is evidence for both increased appetite and altered metabolic control with these drugs • Patient- related factors include pre- existing metabolic issues, and those who are obese, diabetic or pre diabetic, or have high risk lipid profile are more likely to experience problems with these medications than other patients. • Clozapine and olanzapine carry significantly higher risk than other antipsychotics • The potential morbidity of these symptoms has led to the routine recommendations for routine short and long – term monitoring of weight, waist circumference, blood pressure, fasting glucose and lipid profile of patients taking any of the antipsychotics. • All patients should be provided with dietary advice and lifestyle assessment (i.e. patterns of eating, smoking and exercise) and a supportive therapeutic program aimed at better physical health, with special attention to smoking cessation/reduction, exercise and a balanced diet. Community rehabilitation and support programs can be of value. It is also important to monitor bowel function. Constipation is a major and occasionally lethal side-effect of newer antipsychotic medication OTHER ATYPICAL ANTIPSYCHOTICS: SERTINDOLE • Effective agent with a favourable profile of adverse effects • Must be slowly titrated upward to avoid orthostatic hypotension • May cause sinus tachycardia, nasal congestion, and decreased ejaculatory volume • Half life- 3 days, makes it ideal for poorly compliant patients QUETIAPINE • Effective antipsychotic drug associated with no increased risk of extrapyramidal symptoms • Adverse effects: sedation, tachycardia, weight gain and agitation. • Initial dose must be titrated upward over 4 days to avoid orthostatic hypotension and syncope ZIPRASIDONE • Effective drug for the treatment of schizophrenia • Additional benefits for patients with affective symptoms, because it blocks reuptake of serotonin and norepinephrine and for patients with anxiety because it is an agonist for 5 HT1A receptors • Adverse effects: sedation, nausea, dizziness and light headedness • Weight gain • Loss of libido • Hormonal side effects • Sedation • Galactorrhea (stimulation of milk secretions) • Sexual dysfunction in males • Liver disorder (rare) • Constipation ADVERSE PHARMACOLOGIC EFFECTS OF ANTIPSYCHOTIC DRUGS TYPE MANIFESTATION MECHANISM ANS Loss of accommodation, dry mouth, difficulty urinating, constipation Muscarinic cholinoceptor blockade Postural hypotension, impotence Alpha adrenoceptor blockade CNS Parkinson’s syndrome, akathisia, dystonia, Tardive dyskinesia Dopamine receptor blockade ENDOCRINE Amenorrhea, galactorrhea, impotence Dopamine receptor blockade resulting in hyperprolactineamia OTHERS Weight gain Combined H1 and 5HT2 blockade REFERENCE • Benjamin James Saddock, Virginia Alcott Saddock, 2007, Kaplam and Saddock’s. Synopsis of Psychiatry. Behavioral Sciences/Clinical Psychiatry. 10th ed. • Guidelines of drugs commonly used in treating mental illness and related disorders, 1st edition FijiPharmac, MOH • Basic & Clinical Pharmacology, Katzung; 13th Edition • Pharmacology for Health Professionals; Bryant B, Knights K; 2nd edition • uptodate